Exploration of the potential association between GLP-1 receptor agonists and suicidal or self-injurious behaviors: a pharmacovigilance study based on the FDA Adverse Event Reporting System database.
FAERS database
GLP-1RAs
Obesity
Pharmacovigilance
Suicidal or self-injurious behaviors
Type 2 diabetes
Journal
BMC medicine
ISSN: 1741-7015
Titre abrégé: BMC Med
Pays: England
ID NLM: 101190723
Informations de publication
Date de publication:
14 Feb 2024
14 Feb 2024
Historique:
received:
18
08
2023
accepted:
25
01
2024
medline:
15
2
2024
pubmed:
15
2
2024
entrez:
14
2
2024
Statut:
epublish
Résumé
Establishing whether there is a potential relationship between glucagon-like peptide 1 receptor agonists (GLP-1RAs) and suicidal or self-injurious behaviors (SSIBs) is crucial for public safety. This study investigated the potential association between GLP-1RAs and SSIBs by exploring the FDA Adverse Event Reporting System (FAERS) database. A disproportionality analysis was conducted using post-marketing data from the FAERS repository (2018 Q1 to 2022 Q4). SSIB cases associated with GLP-1RAs were identified and analyzed through disproportionality analysis using the information component. The parametric distribution with a goodness-of-fit test was employed to analyze the time-to-onset, and the Ω shrinkage was used to evaluate the potential effect of co-medication on the occurrence of SSIBs. In total, 204 cases of SSIBs associated with GLP-1RAs, including semaglutide, liraglutide, dulaglutide, exenatide, and albiglutide, were identified in the FAERS database. Time-of-onset analysis revealed no consistent mechanism for the latency of SSIBs in patients receiving GLP-1RAs. The disproportionality analysis did not indicate an association between GLP-1RAs and SSIBs. Co-medication analysis revealed 81 cases with antidepressants, antipsychotics, and benzodiazepines, which may be proxies of mental health comorbidities. We found no signal of disproportionate reporting of an association between GLP-1RA use and SSIBs. Clinicians need to maintain heightened vigilance on patients premedicated with neuropsychotropic drugs. This contributes to the greater acceptance of GLP-1RAs in patients with type 2 diabetes mellitus or obesity.
Sections du résumé
BACKGROUND
BACKGROUND
Establishing whether there is a potential relationship between glucagon-like peptide 1 receptor agonists (GLP-1RAs) and suicidal or self-injurious behaviors (SSIBs) is crucial for public safety. This study investigated the potential association between GLP-1RAs and SSIBs by exploring the FDA Adverse Event Reporting System (FAERS) database.
METHODS
METHODS
A disproportionality analysis was conducted using post-marketing data from the FAERS repository (2018 Q1 to 2022 Q4). SSIB cases associated with GLP-1RAs were identified and analyzed through disproportionality analysis using the information component. The parametric distribution with a goodness-of-fit test was employed to analyze the time-to-onset, and the Ω shrinkage was used to evaluate the potential effect of co-medication on the occurrence of SSIBs.
RESULTS
RESULTS
In total, 204 cases of SSIBs associated with GLP-1RAs, including semaglutide, liraglutide, dulaglutide, exenatide, and albiglutide, were identified in the FAERS database. Time-of-onset analysis revealed no consistent mechanism for the latency of SSIBs in patients receiving GLP-1RAs. The disproportionality analysis did not indicate an association between GLP-1RAs and SSIBs. Co-medication analysis revealed 81 cases with antidepressants, antipsychotics, and benzodiazepines, which may be proxies of mental health comorbidities.
CONCLUSIONS
CONCLUSIONS
We found no signal of disproportionate reporting of an association between GLP-1RA use and SSIBs. Clinicians need to maintain heightened vigilance on patients premedicated with neuropsychotropic drugs. This contributes to the greater acceptance of GLP-1RAs in patients with type 2 diabetes mellitus or obesity.
Identifiants
pubmed: 38355513
doi: 10.1186/s12916-024-03274-6
pii: 10.1186/s12916-024-03274-6
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
65Informations de copyright
© 2024. The Author(s).
Références
Lingvay I, Leiter LA. Use of GLP-1 RAs in cardiovascular disease prevention: a practical guide. Circulation. 2018;137:2200–2.
pubmed: 29784677
doi: 10.1161/CIRCULATIONAHA.117.032759
Patorno E, Htoo PT, Glynn RJ, Schneeweiss S, Wexler DJ, Pawar A, et al. Sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists and the risk for cardiovascular outcomes in routine care patients with diabetes across categories of cardiovascular disease. Ann Intern Med. 2021;174:1528–41.
pubmed: 34570599
pmcid: 8969214
doi: 10.7326/M21-0893
Ma X, Liu Z, Ilyas I, Little PJ, Kamato D, Sahebka A, et al. GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential. Int J Biol Sci. 2021;17:2050–68.
pubmed: 34131405
pmcid: 8193264
doi: 10.7150/ijbs.59965
Barritt AS, Marshman E, Noureddin M. Review article: role of glucagon-like peptide-1 receptor agonists in non-alcoholic steatohepatitis, obesity and diabetes-what hepatologists need to know. Aliment Pharmacol Ther. 2022;55:944–59.
pubmed: 35266164
pmcid: 9310586
doi: 10.1111/apt.16794
Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM, et al. Management of Hyperglycemia in Type 2 Diabetes, A consensus report by the american diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022;45(11):2753–86.
pubmed: 36148880
pmcid: 10008140
doi: 10.2337/dci22-0034
Jastreboff AM, Kushner RF. New frontiers in obesity treatment: GLP-1 and nascent nutrient-stimulated hormone-based therapeutics. Annu Rev Med. 2023;74:125–39.
pubmed: 36706749
doi: 10.1146/annurev-med-043021-014919
Bailey CJ, Flatt PR, Conlon JM. An update on peptide-based therapies for type 2 diabetes and obesity. Peptides. 2023;161:170939.
pubmed: 36608818
doi: 10.1016/j.peptides.2023.170939
O’Neil PM, Birkenfeld AL, McGowan B, Mosenzon O, Pedersen SD, Wharton S, et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet. 2018;392:637–49.
pubmed: 30122305
doi: 10.1016/S0140-6736(18)31773-2
Chadda KR, Cheng TS, Ong KK. GLP-1 agonists for obesity and type 2 diabetes in children: systematic review and meta-analysis. Obes Rev. 2021;22:e13177.
pubmed: 33354917
doi: 10.1111/obr.13177
Tan B, Pan X-H, Chew HSJ, Goh RSJ, Lin C, Anand VV, et al. Efficacy and safety of tirzepatide for treatment of overweight or obesity. A systematic review and meta-analysis. Int J Obes (Lond). 2023;47:677–85.
pubmed: 37253796
doi: 10.1038/s41366-023-01321-5
Pfizer Provides Update on GLP-1-RA Clinical Development Program for Adults with Obesity and Type 2 Diabetes Mellitus | Pfizer. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-provides-update-glp-1-ra-clinical-development . Accessed 8 Aug 2023.
Bezin J, Gouverneur A, Pénichon M, Mathieu C, Garrel R, Hillaire-Buys D, et al. GLP-1 receptor agonists and the risk of thyroid cancer. Diabetes Care. 2023;46:384–90.
pubmed: 36356111
doi: 10.2337/dc22-1148
He L, Wang J, Ping F, Yang N, Huang J, Li Y, et al. Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases: a systematic review and meta-analysis of randomized clinical trials. JAMA Intern Med. 2022;182:513–9.
pubmed: 35344001
pmcid: 8961394
doi: 10.1001/jamainternmed.2022.0338
EMA. EMA statement on ongoing review of GLP-1 receptor agonists. European Medicines Agency. 2023. https://www.ema.europa.eu/en/news/ema-statement-ongoing-review-glp-1-receptor-agonists . Accessed 20 Jul 2023.
Fine KL, Rickert ME, O’Reilly LM, Sujan AC, Boersma K, Chang Z, et al. Initiation of opioid prescription and risk of suicidal behavior among youth and young adults. Pediatrics. 2022;149:e2020049750.
pubmed: 35128560
doi: 10.1542/peds.2020-049750
Takeuchi T, Takenoshita S, Taka F, Nakao M, Nomura K. The relationship between psychotropic drug use and suicidal behavior in Japan: Japanese adverse drug event report. Pharmacopsychiatry. 2017;50:69–73.
pubmed: 27595297
Gonda X, Dome P, Serafini G, Pompili M. How to save a life: From neurobiological underpinnings to psychopharmacotherapies in the prevention of suicide. Pharmacol Ther. 2023;244:108390.
pubmed: 36940791
doi: 10.1016/j.pharmthera.2023.108390
Hughes JL, Horowitz LM, Ackerman JP, Adrian MC, Campo JV, Bridge JA. Suicide in young people: screening, risk assessment, and intervention. BMJ. 2023;381:e070630.
pubmed: 37094838
doi: 10.1136/bmj-2022-070630
Jing Y, Liu J, Ye Y, Pan L, Deng H, Wang Y, et al. Multi-omics prediction of immune-related adverse events during checkpoint immunotherapy. Nat Commun. 2020;11:4946.
pubmed: 33009409
pmcid: 7532211
doi: 10.1038/s41467-020-18742-9
Raschi E, Fusaroli M, Giunchi V, Repaci A, Pelusi C, Mollica V, et al. adrenal insufficiency with anticancer tyrosine kinase inhibitors targeting vascular endothelial growth factor receptor: analysis of the FDA adverse event reporting system. Cancers (Basel). 2022;14:4610.
pubmed: 36230533
doi: 10.3390/cancers14194610
Xia S, Gong H, Zhao Y, Guo L, Wang Y, Ma R, et al. Tumor lysis syndrome associated with monoclonal antibodies in patients with multiple myeloma: a pharmacovigilance study based on the FAERS database. Clin Pharmacol Ther. 2023;114:211–9.
pubmed: 37086211
doi: 10.1002/cpt.2920
Zhou J, Wei Z, Xu B, Liu M, Xu R, Wu X. Pharmacovigilance of triazole antifungal agents: analysis of the FDA adverse event reporting system (FAERS) database. Front Pharmacol. 2022;13:1039867.
pubmed: 36588707
pmcid: 9798094
doi: 10.3389/fphar.2022.1039867
Ren W, Wang W, Guo Y. Analysis of adverse reactions of aspirin in prophylaxis medication Based on FAERS database. Comput Math Methods Med. 2022;2022:7882277.
pubmed: 35664643
pmcid: 9162824
doi: 10.1155/2022/7882277
Yu RJ, Krantz MS, Phillips EJ, Stone CA. Emerging causes of drug-induced anaphylaxis: a review of anaphylaxis-associated reports in the fda adverse event reporting system (FAERS). J Allergy Clin Immunol Pract. 2021;9:819–829.e2.
pubmed: 32992044
doi: 10.1016/j.jaip.2020.09.021
Hu Y, Bai Z, Tang Y, Liu R, Zhao B, Gong J, et al. Fournier gangrene associated with sodium-glucose cotransporter-2 inhibitors: a pharmacovigilance study with data from the U.S. FDA Adverse event reporting system. J Diabetes Res. 2020;2020:3695101.
pubmed: 32695827
pmcid: 7368210
doi: 10.1155/2020/3695101
Liu L, Chen J, Wang L, Chen C, Chen L. Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: a real-world disproportionality study based on FDA adverse event reporting system database. Front Endocrinol (Lausanne). 2022;13:1043789.
pubmed: 36568085
doi: 10.3389/fendo.2022.1043789
Hetrick SE, McKenzie JE, Bailey AP, Sharma V, Moller CI, Badcock PB, et al. New generation antidepressants for depression in children and adolescents: a network meta-analysis. Cochrane Database Syst Rev. 2021;5:CD013674.
pubmed: 34029378
Sauzet O, Carvajal A, Escudero A, Molokhia M, Cornelius VR. Illustration of the weibull shape parameter signal detection tool using electronic healthcare record data. Drug Saf. 2013;36:995–1006.
pubmed: 23673816
doi: 10.1007/s40264-013-0061-7
van Puijenbroek EP, Bate A, Leufkens HGM, Lindquist M, Orre R, Egberts ACG. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf. 2002;11:3–10.
pubmed: 11998548
doi: 10.1002/pds.668
Norén GN, Hopstadius J, Bate A. Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery. Stat Methods Med Res. 2013;22:57–69.
pubmed: 21705438
doi: 10.1177/0962280211403604
Trillenberg P, Sprenger A, Machner B. Sensitivity and specificity in signal detection with the reporting odds ratio and the information component. Pharmacoepidemiol Drug Saf. 2023;32:910–7.
pubmed: 36966482
doi: 10.1002/pds.5624
Noguchi Y, Tachi T, Teramachi H. Comparison of signal detection algorithms based on frequency statistical model for drug-drug interaction using spontaneous reporting systems. Pharm Res. 2020;37:86.
pubmed: 32356247
doi: 10.1007/s11095-020-02801-3
Anderson N, Borlak J. Correlation versus causation? Pharmacovigilance of the analgesic flupirtine exemplifies the need for refined spontaneous ADR reporting. PLoS One. 2011;6:e25221.
pubmed: 22022383
pmcid: 3191146
doi: 10.1371/journal.pone.0025221
Fusaroli M, Raschi E, Giunchi V, Menchetti M, Rimondini Giorgini R, De Ponti F, et al. Impulse control disorders by dopamine partial agonists: a pharmacovigilance-pharmacodynamic assessment through the FDA adverse event reporting system. Int J Neuropsychopharmacol. 2022;25:727–36.
pubmed: 35639870
pmcid: 9515127
doi: 10.1093/ijnp/pyac031
Raschi E, Fusaroli M, Ardizzoni A, Poluzzi E, De Ponti F. Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment. Breast Cancer Res Treat. 2021;186:219–27.
pubmed: 33150548
doi: 10.1007/s10549-020-06001-w
Horska K, Ruda-Kucerova J, Skrede S. GLP-1 agonists: superior for mind and body in antipsychotic-treated patients? Trends Endocrinol Metab. 2022;33:628–38.
pubmed: 35902330
doi: 10.1016/j.tem.2022.06.005
Kelly AS, Auerbach P, Barrientos-Perez M, Gies I, Hale PM, Marcus C, et al. A randomized, controlled trial of liraglutide for adolescents with obesity. N Engl J Med. 2020;382:2117–28.
pubmed: 32233338
doi: 10.1056/NEJMoa1916038
O’Neil PM, Aroda VR, Astrup A, Kushner R, Lau DCW, Wadden TA, et al. Neuropsychiatric safety with liraglutide 3.0 mg for weight management: Results from randomized controlled phase 2 and 3a trials. Diabetes Obes Metab. 2017;19:1529–36.
pubmed: 28386912
pmcid: 5655710
doi: 10.1111/dom.12963
Li J-R, Cao J, Wei J, Geng W. Case report: Semaglutide-associated depression: a report of two cases. Front Psychiatry. 2023;14:1238353.
pubmed: 37706035
pmcid: 10495976
doi: 10.3389/fpsyt.2023.1238353
Klinitzke G, Steinig J, Blüher M, Kersting A, Wagner B. Obesity and suicide risk in adults–a systematic review. J Affect Disord. 2013;145:277–84.
pubmed: 22871535
doi: 10.1016/j.jad.2012.07.010
da Silva Bandeira BE, Dos Santos Júnior A, Dalgalarrondo P, de Azevedo RCS, Celeri EHVR. Nonsuicidal self-injury in undergraduate students: a cross-sectional study and association with suicidal behavior. Psychiatry Res. 2022;318:114917.
pubmed: 36332506
doi: 10.1016/j.psychres.2022.114917
Yan Y, Gong Y, Jiang M, Gao Y, Guo S, Huo J, et al. Utilization of glucagon-like peptide-1 receptor agonists in children and adolescents in China: a real-world study. Front Endocrinol (Lausanne). 2023;14:1170127.
pubmed: 37383395
doi: 10.3389/fendo.2023.1170127
Dubé JP, Smith MM, Sherry SB, Hewitt PL, Stewart SH. Suicide behaviors during the COVID-19 pandemic: a meta-analysis of 54 studies. Psychiatry Res. 2021;301:113998.
pubmed: 34022657
pmcid: 9225823
doi: 10.1016/j.psychres.2021.113998
Yaribeygi H, Sathyapalan T, Sahebkar A. Molecular mechanisms by which GLP-1 RA and DPP-4i induce insulin sensitivity. Life Sci. 2019;234:116776.
pubmed: 31425698
doi: 10.1016/j.lfs.2019.116776
Jespersen MJ, Knop FK, Christensen M. GLP-1 agonists for type 2 diabetes: pharmacokinetic and toxicological considerations. Expert Opin Drug Metab Toxicol. 2013;9:17–29.
pubmed: 23094590
doi: 10.1517/17425255.2013.731394
Gliatto MF, Rai AK. Evaluation and treatment of patients with suicidal ideation. Am Fam Physician. 1999;59:1500–6.
pubmed: 10193592
Battini V, Van Manen RP, Gringeri M, Mosini G, Guarnieri G, Bombelli A, et al. The potential antidepressant effect of antidiabetic agents: New insights from a pharmacovigilance study based on data from the reporting system databases FAERS and VigiBase. Front Pharmacol. 2023;14:1128387.
pubmed: 36873988
pmcid: 9981969
doi: 10.3389/fphar.2023.1128387
Darwish AB, El Sayed NS, Salama AAA, Saad MA. Dulaglutide impedes depressive-like behavior persuaded by chronic social defeat stress model in male C57BL/6 mice: Implications on GLP-1R and cAMP/PKA signaling pathway in the hippocampus. Life Sci. 2023;320:121546.
pubmed: 36878280
doi: 10.1016/j.lfs.2023.121546
Rubino DM, Greenway FL, Khalid U, O’Neil PM, Rosenstock J, Sørrig R, et al. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial. JAMA. 2022;327:138–50.
pubmed: 35015037
pmcid: 8753508
doi: 10.1001/jama.2021.23619
Rubino D, Abrahamsson N, Davies M, Hesse D, Greenway FL, Jensen C, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021;325:1414–25.
pubmed: 33755728
doi: 10.1001/jama.2021.3224
Wadden TA, Bailey TS, Billings LK, Davies M, Frias JP, Koroleva A, et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA. 2021;325:1403–13.
pubmed: 33625476
doi: 10.1001/jama.2021.1831
Davies M, Færch L, Jeppesen OK, Pakseresht A, Pedersen SD, Perreault L, et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021;397:971–84.
pubmed: 33667417
doi: 10.1016/S0140-6736(21)00213-0
Sakaeda T, Tamon A, Kadoyama K, Okuno Y. Data mining of the public version of the FDA adverse event reporting system. Int J Med Sci. 2013;10:796–803.
pubmed: 23794943
pmcid: 3689877
doi: 10.7150/ijms.6048
Khaleel MA, Khan AH, Ghadzi SMS, Adnan AS, Abdallah QM. A Standardized dataset of a spontaneous adverse event reporting system. Healthcare (Basel). 2022;10:420.
pubmed: 35326898
doi: 10.3390/healthcare10030420
McIntyre RS, Mansur RB, Rosenblat JD, Kwan ATH. The association between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: reports to the Food and Drug Administration Adverse Event Reporting System (FAERS). Expert Opin Drug Saf. 2023;1–9. Online ahead of print.
Chen C, Zhou R, Fu F, Xiao J. Postmarket safety profile of suicide/self-injury for GLP-1 receptor agonist: a real-world pharmacovigilance analysis. Eur Psychiatry. 2023;66:e99.
pubmed: 38031404
pmcid: 10755578
doi: 10.1192/j.eurpsy.2023.2474
Wang W, Volkow ND, Berger NA, Davis PB, Kaelber DC, Xu R. Association of semaglutide with risk of suicidal ideation in a real-world cohort. Nat Med. 2024. https://doi.org/10.1038/s41591-023-02672-2 .
doi: 10.1038/s41591-023-02672-2
pubmed: 38302715